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Foreword  
The opportunity to write a thesis is a chance to finally summarize all of the work that you and 
your group have done over the past four years and to be proud of what you achieved together. 
The group started in the beginning of 2010 with only Andreas, Dhifaf and me and we were 
eager to get started with doing all the things that we heard Andreas had done back in the 
States. We had the aspiration that we would become a well-known NK cell group at KI and 
that our research would one day form the basis for a clinical trial testing NK cell-based 
therapy in cancer patients. Today, four years later, these aspirations are still very much alive 
and our contributions to the scientific community have finally started to bear fruit. And yes, 
the aspiration that NK cells can be used to treat cancer patients in Sweden is still there and 
within grasp. For helping me keep these dreams alive despite setbacks and disappointments, I 
can only thank my supervisor and friend Andreas Lundqvist. I know that the future is as 
bright and as confident as an NK cell expressing loads of NKG2D and CXCR3. 
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The product of mental labor - science - 
always stands far below its value, because 
the labor-time necessary to reproduce it 
has no relation at all to the labor-time 
required for its original production. 
Karl Marx 
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Populärvetenskaplig sammanfattning 
När en genetisk skada uppstår i en cell kan det leda till mutationer. Cellen försöker då att 
reparera skadan men om detta misslyckas försöker den ta död på sig själv genom så kallad 
programmerad celldöd. Om även detta misslyckas riskerar cellen att utsättas för ytterligare 
mutationer och utveckla egenskaper som bland annat gör att den börjar dela sig okontrollerat 
och bilda en tumör. Vårt immunförsvar består av flera olika celltyper som har till uppgift att 
bekämpa infektioner men som också hjälper kroppen att upptäcka och oskadliggöra 
cancerceller. I och med att cancerceller utvecklas från den egna kroppen så är det svårare för 
immunförsvaret att känna igen dem som något farligt i motsats till t.ex. bakterier och virus 
som kommer utifrån. Den immuncell som är mest effektiv på att känna igen och ta död på 
tumörceller är de så kallade natural killer (NK) cellerna. NK cellerna patrullerar våra kroppar 
under hela vår livstid och de interagerar ständigt med omgivande celler för att kontrollera om 
de har blivit infekterade med virus eller om de har kännetecken av tumörceller.  
Immunterapi mot cancer kan utformas på många olika sätt och under senare år har potentialen 
av NK celler börjat utnyttjas för att behandla patienter med avancerad cancer. Så kallad 
adoptiv NK cellterapi går ut på att man isolerar NK celler från blodet på en cancerpatient eller 
en frisk donator. Dessa celler kan sedan odlas och manipuleras under varierande former i 
laboratoriet för att få NK cellerna att dela sig och för att få dem att bli bättre på att känna igen 
och döda olika typer av cancer. Denna process, vilken kallas expansionsfasen, tar ca två 
veckor och under tiden behandlas patienten med t.ex. cytostatika och stålningsterapi. Detta 
görs både för att bekämpa cancern men också för att ta bort patientens kvarvarande 
immunceller så att det finns plats i blodet när man sedan sprutar in de expanderade NK 
cellerna. 
I den här avhandlingen har vi studerat hur man kan förbättra adoptiv NK cellterapi genom att 
angripa tre olika problem som i nuläget hindrar den kliniska effektiviteten av NK cellsterapi. 
1) Öka tumörcellernas känslighet för avdödning av NK celler. Här har vi upptäckt att genom 
att behandla tumörer med låga doser av cytostatika så ökar deras känslighet för att bli dödade 
av NK celler. Vi har även studerat hur man kan förbättra NK cellers förmåga att döda 
tumörceller genom att manipulera dem i laboratoriet 2) Öka migreringen av NK celler mot  
tumörer. I detta projekt har vi i möss studerat hur NK celler som sprutas in i blodet kan 
förflytta sig mot tumörer och infiltrera dem. Här har vi även utvärderat vilken anti-tumör 
effekt som infiltrationen medför. 3) Identifiera tumörer som är naturligt känsliga för NK 
cellterapi. Vi har upptäckt att den mycket aggresiva tumörtypen anaplastisk sköldkörtelcancer 
både är naturligt känslig för avdödning av NK celler och utsöndrar signalsubstanser som får 
NK celler att migrera mot tumören. Dessa egenskaper gör att patienter med anaplastisk 
sköldkörtelcancer, vilka i nuläget inte har tillgång till någon botande behandling, i framtiden 
skulle hjälpas av NK cell-baserad immunterapi.  
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Abstract 
The role of natural killer (NK) cells in cancer development has been studied extensively over 
the last four decades and the increasing knowledge on NK cell regulation has improved both 
safety and efficacy of treatment. Despite these recent advances the clinical success has to date 
been modest in treatment of solid tumors, owing both to suboptimal directed migration of NK 
cells and the tumor cell’s resistance to NK cell-mediated lysis. This thesis focuses on 
strategies to overcome these critical issues thus improving the anti-tumor effect of adoptive 
NK cell therapy. In paper I, we have studied the sensitizing effect of doxorubicin on tumor 
cells to NK cell and T cell-mediated lysis. The potential clinical advantage of using 
doxorubicin as a preconditioning agent was highlighted in a xenograft mouse model, where 
mice receiving low-doses of doxorubicin prior to NK cell infusion had a stronger anti-tumor 
effect of a subsequent NK cell treatment compared to mice receiving only NK cell treatment. 
Further, we identified TRAIL-signaling as the main pathway responsible for the tumor 
sensitization due to decreased expression of the anti-apoptotic protein cFLIP. In paper II we 
have established that the cytotoxicity of NK cells can be augmented by co-culturing them 
with monocytes in presence of the biphosphonate zoledronic acid (ZA). We observed an 
upregulated expression of TRAIL on NK cells, through increased levels of monocyte-derived 
IFNγ in the culture. Thus, NK cells primed with ZA were able to lyse TRAIL-sensitive 
tumors both in vitro and in vivo. In paper III, we studied CXCL10-mediated migration of NK 
cells toward solid tumors. We found that ex vivo expansion of NK cells induced a 10-fold 
increase in CXCR3-receptor expression, which allowed them to migrate towards tumor cells 
in a CXCL10-dependent manner. In two separate xenograft models we could demonstrate the 
anti-tumor effect of CXCL10-induced migration of adoptively transferred CXCR3-positive 
NK cells by their selective targeting of CXCL10-producing tumors, which resulted in reduced 
tumor progression and prolonged survival. In paper IV, we identified anaplastic thyroid 
carcinoma (ATC) as a potential novel target for NK cell therapy. We found that ATC cells 
were sensitive to NKG2D-mediated lysis due to high expression of ULBP2 on tumor cells. In 
addition, tumor cells produced high levels of CXCL10 which attracted CXCR3-positive NK 
cells in vitro. In ATC tumor samples we found a suppressed NK cell population although 
enriched for CXCR3 expression suggesting that CXCL10 may have been involved in the 
chemoattraction of the NK cells.  
In conclusion, we have studied some of the important aspects of how NK cells interact with 
tumor cells and suggested approaches that could improve the use of NK cells in cancer 
therapy. Moreover, we have identified the highly aggressive tumor ATC as being uniquely 
sensitive to NK cell lysis and have studied the prospects of developing NK cell therapies for 
ATC patients. 
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1.    Introduction 
Throughout history, all organisms on earth have developed defense mechanisms that allow 
them to cope with challenges in their surrounding environment. In higher species, these 
mechanisms are collectively known as the immune system. For organisms to be able to 
develop into more advanced creatures, a genome with a certain degree of instability is 
required. This allows for mutations to occur that can potentially lead to increased survival 
benefit which is the essence of evolution. However, the price of our ability to evolve is the 
risk of developing cancer resulting from mutations that cause irreparable genetic damage to 
the host cell resulting in additional mutations which ultimately initiates the growth of a tumor. 
The human immune system, which is extremely complex in its organization, has evolved not 
only to combat external threats such as viruses, bacteria, parasites or other pathogens but has 
also developed mechanisms that screen the body for cells that has been malignantly 
transformed and needs to be eliminated. The idea that the immune system is involved in the 
elimination of tumors dates back to the early 20th century when Paul Ehrlich hypothesized 
that, without an immune system, the body would be overrun by an “overwhelming frequency” 
of carcinomas [1]. However, it was not until decades later in 1957 that the concept of immune 
surveillance was first described by Sir F McFarlane Burnet and his seminal discovery paved 
the way for future research in the field of tumor immunology [2-4]. The natural killer (NK) 
cell was described in 1975 and when its functional regulation was established in the early 
1980s by researchers at Karolinska Institutet, it sparked a boom in NK cell research which 
later showed that NK cells play a major role in the natural immune response against malignant 
cells due to their simple, yet elegant, function of recognizing cells unable to show that they 
belong to the host [5-8].  
In this thesis I will discern how NK cells can be used in treatment of cancer. The prospects, as 
well as the hurdles, will be discussed and I will focus on the central questions that determine 
whether a cancer is or can become susceptible to NK cell therapy. 
I will start to give a general introduction to the human immune system and proceed with a 
more detailed explanation of the subjects that are essential to understand and interpret my 
findings. 
1.1    Overview of the immune system   
The human immune system is composed of two arms that complement each other in the 
defense against different pathogens; the innate and adaptive immune system. The innate 
immune system consists of phagocytes such as macrophages and neutrophils as well as 
dendritic cells (DCs) and NK cells. The innate effector cells are equipped with germline 
encoded receptors that are known as pattern recognition receptors (PPRs). With the use of 
PPRs, phagocytes can recognize pathogen-associated molecular patterns (PAMPs), which are 
structures specifically expressed by for instance bacteria (lipopolysaccharides (LPS)) or 
viruses (single stranded DNA). Upon ligation of the PPRs, the phagocytes are activated and 
triggered to either engulf the bacteria or infected cells or alternatively release cytotoxic 
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granules against their targets. Meanwhile, a subset of phagocytic cells known as antigen 
presenting cells (APC) of which DCs are the most potent, display fragments of the engulfed 
pathogens (antigens) on their cell surface and travel to the secondary lymphoid organs 
(SLOs)1
Human T cells are comprised of two main subsets; the CD8+ T cells, also known as cytotoxic 
T lymphocytes (CTLs) bind to MHC class I molecules on APCs and are the main effectors 
cells that, after a clonal expansion, are deployed to specifically target and eliminate the 
pathogen-infected or cancerous cells. The CD4+ T cells also known as the helper T cells (TH), 
bind to MHC class II molecules on APCs and are, like the name suggests, important 
regulators of immune responses by activating other immune cells such as B cells, phagocytic 
cells as well as CTLs. The cellular immune response is also complemented by the humoral 
component of the immune system which is comprised of soluble macromolecules including 
antimicrobial peptides, complement proteins and most importantly antibodies 
(immunoglobulins). When B cells are primed they differentiate into plasma cells that are 
potent producers of antibodies. Antibodies that bind molecules on the microbe surface have 
several mechanisms of action; firstly, by blocking the binding of the microbe with host cells 
they neutralize their interaction. Secondly, they facilitate the engulfment of the microbe by 
acting as a flag for phagocytes to recognize and take up the microbe. A process termed 
opsonization. Thirdly, bound antibodies can be recognized by cytotoxic lymphocytes that 
express receptors for the Fc-portion of antibodies and subsequently induce antibody-
dependent cell-mediated cytotoxicity (ADCC) directed against the opsonized target cells. 
Depending on the nature of the invading microbe, the immune responses can be skewed in 
different ways to most effectively clear the infection. In the case of microbes that infect and 
replicate in host cells, such as viruses or intracellular bacteria, a TH1 response is elicited. In 
contrast, a TH2 response is generated in response to extracellular bacteria or parasites [
. Here, they interact with adaptive immune cells (B and T cells) that can recognize 
and respond to an almost unlimited amount of different pathogens. This potential is achieved 
by random genetic rearrangement of the cells’ recognition receptors creating a vast pool of 
cells in the SLOs that all have different specificities and are ready to be primed by any 
divisible pathogen. When the APCs come in contact with a lymphocyte that expresses a 
receptor that can recognize the presented antigen, the lymphocyte starts to clonally expand 
ultimately generating an army of clonally selected lymphocytes that are ready to engage the 
invading pathogens with high specificity. In contrast to innate immune cells, B and T cells can 
generate memory cells that can quickly and with a stronger magnitude respond to future 
exposures of the same antigen.  
9].  
                                               
 
1 Lymph nodes and spleen 
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1.1.1    Cytokine signaling 
Immune cells communicate with each other and with other cells in the body both through 
direct cell-cell contact but also through soluble proteins called cytokines. Through this 
communication they can orchestrate the actions of an immune response by regulating a 
variety of cellular responses including differentiation, proliferation and activation. 
Importantly, cytokine signaling is also used to maintain homeostasis of the immune system 
when an infection is cleared. The type I interferons (IFNs) are important regulators during 
viral infections. They are released from infected cells and modulate surrounding cells to 
prevent them from taking up the virus while also stimulating antigen presentation by APCs 
and increased activation of NK cells [10]. Type II interferon or interferon-gamma (IFNγ) is 
produced by immune cells (primarily T cells and NK cells) and trigger activation of several 
immune cells including increased microbicidal function of macrophages, isotype switching of 
B cells and TH1 polarization of T cells. To increase antigen presentation and priming of T 
cells a wide variety of cells respond to IFNγ by upregulating major histocompatibility (MHC) 
class I as well as MHC class II receptors on the cell surface [11]. I will discuss the clinical 
implications of this phenomenon later in this thesis. Among the interleukins (ILs), IL-2 is one 
of the major players in regulating the actions of immune cells during an immune response. IL-
2 is produced by T cells and by other cells such as NK cells and DCs, although in smaller 
amounts, and stimulates survival, proliferation and activation of T cells, NK cells and other 
lymphocytes [12]. After antigen exposure, IL-2 production is greatly increased and promotes 
both T cell expansion as well as memory generation [13]. Lately, IL-15 has been shown to be 
an important cytokine to promote NK cells survival and proliferation [14-16].  
1.1.2    Lymphocyte migration and chemokines 
When a lymphocyte commits to move in a particular direction, the morphology of the actin 
cytoskeleton is polarized to elongate the cell, forming a wide leading edge (pseudopod) in the 
direction of locomotion and a tail-like structure (uropod) in the trailing end [17]. In the case of 
chemokine-induced migration, the chemokine receptors accumulate in the leading pseudopod 
to allow for increased perception of the chemokine gradient [18]. A lymphocyte that travels 
through a vessel can responds to immobilized chemokines on the walls of endothelial cells 
(ECs) by tethering to the vessel wall followed by rolling, increased adhesion to the ECs and 
ultimately transmigration through the vessel wall [19]. In contrast, when soluble blood-borne 
chemokines bind to chemokine receptors on circulating lymphocytes, they inhibit their 
adhesion to ECs thus promoting continued circulation. 
There are currently fifty chemokines and twenty chemokine receptors described in human and 
through their interplay the migratory patterns of immune cells are orchestrated. By directing 
migration of leukocytes and other cells to sites of inflammation, such as an infected wound or 
an emerging tumor, chemokines control the recruitment and retention of particular subsets of 
cells. Although chemokine signaling is generally promiscuous in its receptor-ligand 
interactions, where many of the genes are clustered in the same chromosomal loci, the so 
called “homeostatic” chemokines (e.g. CXCL14, CCL19 and CCL21) are constitutively 
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expressed and direct the homing of CCR7+ naïve T cells and DCs to SLOs for priming [20]. 
After priming, some T cells lose expression of CCR7 to release them from recirculation in 
SLOs and acquire expression of inflammatory chemokine receptors allowing further 
migration to sites of inflammation. These T cells are termed effector memory T cells (TEM). 
The central memory T cells (TCM) retain their CCR7-expression and co-express CD62L 
allowing them to home to lymph nodes. Upon a second stimulation by DCs they can rapidly 
differentiate to effector T cells [21, 22]. Upon initiation of a humoral immune response, CD4+ 
T cells acquire expression of CXCR5 allowing them to respond to CXCL13 which is secreted 
from follicles and promotes interaction with B cells.  
Pro-inflammatory chemokine signaling has traits of both pleiotropism and redundancy 
meaning that chemokines can bind several receptors triggering different functions and that 
chemokine receptors can be stimulated by several different chemokines triggering the same 
response [23, 24]. Pro-inflammatory chemokines can have antagonistic functions shaping the 
immune response between TH1 and TH2 responses [25]. The chemokines CXCL92, CXL103 
and CXCL114
26
 are agonists to cells expressing the CXCR3 receptor including activated TH1 
cells  and CTLs as well as innate lymphocytes such as NK cells [ ]. However, these 
chemokines are natural antagonists to the CCR3 receptor which is expressed on the basophils 
and eosinophils [27, 28], cells that are part of a TH2 immune response. The CXCR3-ligands 
are inducible by IFNγ, a TH1 cytokine which is produced in areas of inflammation as well as 
in the tumor microenvironment. CXCL10 together with other inflammatory chemokines 
including CX3CL15
29
 has been identified as major predictive factors for infiltration of CTLs in 
colorectal cancer as well as other cancers [ ]. Galon and colleagues has pioneered the 
concept of immunoscoring which is a novel system for staging of tumors where the 
localization and density of infiltrating lymphocytes forms the basis for the prediction of tumor 
progression and clinical outcome [30]. The strength of the prediction by immunoscoring is 
another indication of how important the immune system is in the control of tumor growth and 
dissemination. 
1.2    NK cells 
NK cells are large granular lymphocytes that constitute an important part of the innate 
immune system. They were identified by Dr. Rolf Kiessling and colleagues in 1975 by 
analysis of their functional ability to kill tumor cells without prior sensitization [5, 31]. A 
decade later, Kärre and colleagues formulated the “missing self hypothesis” based on the 
finding that NK cells target cells with low or absent expression of MHC class I molecules [8].  
                                               
 
2 Monokine induced by interferon gamma (MIG) 
3 Interferon gamma-induced protein 10 (IP-10) 
4 Interferon-inducible T cell alpha chemoattractant (I-TAC) 
5 Fractalkine 
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In this thesis I have exclusively studied human NK cells and will only sparingly discuss 
findings from NK cell mouse models for the sake of clarity. NK cells originate from lymphoid 
progenitors in the bone marrow, where they acquire expression of NK cell specific receptors.  
The first to appear are the natural cytotoxicity receptor NKp46 and CD161c as well as the 
chemokine receptor CXCR4 of which the latter is needed to retain the developing NK cells in 
the bone marrow that contain high levels of the CXCR4 ligand CXCL12 [32, 33]. An 
important developmental step, which the NK cells share with other lymphoid cells, is the 
acquisition of the IL-2 receptor γ-chain since cells depend on stimulation by both IL-2 and IL-
15 for their differentiation, proliferation and survival. NK cells can be subdivided into two 
phenotypically and functionally distinct subsets based on their expression of CD56 on the cell 
surface. The CD56bright NK cells comprise around 10% of circulating NK cells and have an 
immunoregulatory role by secretion of proinflammatory cytokines although they have poor 
cytotoxic capacity. The CD56dim NK cell subset, which is believed to be in a more mature 
state than the CD56bright NK cells, are highly granular and have potent cytolytic capacity [34] 
Aside from their direct cytotoxicity toward virally infected cells or tumor targets, NK cells 
have a role in directing the immune response by interacting with other immune cells.  They do 
this either through secretion of pro-inflammatory cytokines such as tumor necrosis factor α 
(TNFα) and IFNγ which has diverse and potent anti-viral effects but also by direct cell-cell 
contact with DCs [35-38]. Although NK cells are part of the innate immune system, they have 
recently been found to possess traits that, under certain experimental conditions, resemble 
adaptive immune cells. Sun and colleagues demonstrated that NK cells expressing the virus-
specific Ly49H receptor, responded to a murine cytomegalovirus (mCMV) infection with a 
potent proliferation phase followed by the generation of Ly49H+ cells that resided in the 
lymphoid organs for several months. When the “memory-like” NK cells were adoptively 
transferred to naïve syngeneic mice that were challenged with murine CMV, they underwent a 
secondary expansion phase conferring protection against the virus [39]. In humans, the 
existence of memory NK cells has not been established although it has been demonstrated in 
viral infections including hanta-virus, chikungunya virus and human cytomegalovirus 
(hCMV), that a certain subset of terminally differentiated NKG2C+ NK cells can undergo re-
expansion when transferred to a second seropositive host [40-42].   
1.2.1    Regulation of NK cell cytotoxicity 
NK cells express a range of germline encoded receptors with the capacity to induce cytotoxic 
functions of the NK cells when ligated with their target molecules. These target molecules are 
normal self proteins that are generally expressed in low levels in healthy cells but can be 
upregulated upon cellular stress such as infection of transformation thus gaining the potential 
to activate NK cells. The actions of NK cells are however tightly regulated by inhibitory 
receptors which bind to MHC class I molecules which are expressed on all nucleated cells 
[43]. It is the net sum of activating and inhibitory signals that NK cells receive from its 
interactions with target cells that determine whether it is activated to kill the target cell or not 
[44-47] (figure 1). This control mechanism safeguards normal cells from triggering activation 
of NK cells and being eliminated.  
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1.2.1.2 Inhibitory receptors 
In humans, the killer-cell immunoglobulin-like receptors (KIRs) are the main inhibitory 
receptors. They recognize and bind to the classical MHC class I molecules human leukocyte 
antigen (HLA)-A, -B and -C while the CD94/NKG2A dimer binds to the non-classical MHC 
class I molecule HLA-E [48-50]. The MHC class I molecules are expressed on all healthy 
nucleated cells but may be downregulated or lost after viral infection or malignant 
transformation of cells or as a result of immune evasion by an evolving tumor [51-53]. The 
KIRs that have long cytoplasmic tails deliver their inhibitory signal via immunoreceptor 
tyrosine-based inhibitory motifs (ITIMs) that can shut down NK cell activation through 
dephosphorylation of activating adaptor molecules. In contrast, there are KIRs with short 
cytoplasmic domains that can mediate activation instead of inhibition [54].  The finding that 
every individual person differ in their repertoire of KIR genes and that individual NK cells 
express different KIR gene products inspired researchers to investigate how the KIR 
repertoire is established and how tolerance is achieved. Indeed, when an NK cell expressing a 
specific KIR, interacts with a target cell that lacks a specific HLA-allele corresponding to the 
KIR, the NK cell is activated and the target cell is lysed in accordance with the missing self 
hypothesis. However, in MHC class I-deficient mouse models, NK cells were hyporesponsive 
[55]. Moreover, in humans where NK cells without any expression of inhibitory receptors 
targeting MHC class I were identified, these cells were also hyporesponsive indicating that 
the missing self hypothesis needed further fine-tuning [56, 57]. A hypothesis was put forward 
to explain these phenomena and how NK cells maintain their tolerance to self. The term 
“licensing” was born which proposed that NK cells need to interact with self MHC class I 
molecules to become fully mature and acquire their license to kill [58]. 
1.2.1.3 Activating receptors 
There is a multitude of membrane bound activating receptors that can act in synergy to deliver 
intracellular activation signals to NK cells [59, 60]. The activating receptors employ different 
intracellular signaling pathways as opposed to inhibitory receptors which all recruit Src 
homology 2 domain-containing phosphatase 1 (SHP-1) to dephosphorylate cytoplasmic 
ITIMs thus delivering their inhibitory signal [61]. The natural cytotoxicity receptors (NCRs) 
NKp30 and NKp46 are expressed on resting NK cells while NKp44 is expressed only on 
activated NK cells [62-65]. These receptors as well as the Fcγ-receptor CD16 signal via the 
immunoreceptor tyrosine-based activation motif (ITAM) that associates with the tyrosine 
kinases Syk and ζ-associated protein of 70 kDa (ZAP-70) [66]. Efforts to characterize the 
NCR ligands are currently underway and so far the only well-defined ligand is the NKp30 
ligand B7-H6 which has been found to be expressed on tumor cells as well as 
proinflammatory monocytes and neutrophils [67, 68].  
Other important activating NK cell receptors are natural killer group 2 member D (NKG2D), 
DNAX-accessory molecule-1 (DNAM-1) and the CD2 family members which, upon IL-2 
activation of NK cells, can act in synergy to induce lysis of target cells [69]. The ligands for 
NKG2D are the major histocompatibility complex class I chain-related chain (MIC) A and B 
and the UL16 binding proteins (ULBP) 1-6 [70-74]. It has been demonstrated that NKG2D-
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ligands are upregulated upon cellular stress and that several NKG2D-ligands are 
overexpressed in human cancers [75-77]. Moreover, mice bearing tumors with ectopic 
expression of NKG2D-ligands overcome MHC-class I-induced inhibition of NK cells, thus 
promoting rejection of the tumors [78]. The binding of integrin-receptor lymphocyte function-
associated antigen-1(LFA-1) to the intercellular adhesion molecule (ICAM) -1 or -2 on target 
cells triggers an adhesion and early activation of NK cells which is important for subsequent 
polarization and degranulation of the NK cell against its target [79].    
1.2.1.4 Regulation of NK cell killing 
A feature that NK cells share with CTLs is the capacity to exocytose granules containing 
perforin and granzyme as well as other lytic proteins [80]. These proteins work in concert to 
permeabilize and induce apoptosis in the target cells [81, 82]. The importance of the 
perforin/granzyme mechanism for NK cell and T cell cytotoxicity against tumors has been 
highlighted in several murine models [83, 84]. NK cells as well as T cells are able to employ 
an entirely different mode of cytotoxicity by engagement of so called death ligands including 
TNF-related apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL). These ligands bind to 
death receptors (DRs) on target cells and initiate apoptosis through activation of the caspase-8 
intracellular pathway [85-87] (figure 1). TRAIL is expressed on activated NK cells and can be 
upregulated by stimulation with IL-2 or IL-15 [88]. The role of NK cell-mediated elimination 
of tumors via TRAIL has been demonstrated in murine tumor models, where treatment with 
neutralizing antibodies against TRAIL promoted progression of subcutaneously inoculated 
TRAIL-sensitive tumors [89]. The activating receptors for TRAIL are the TRAIL-R16  and 
TRAIL-R27
90-92
  which upon ligation with TRAIL trimerizes the ligand leading to recruitment of 
Fas-associated protein with death domain (FADD) and assembly of the death-inducing 
signaling complex (DISC) which subsequently autocatalytically cleaves caspase-8 [ ]. 
From here, the propagation of the apoptotic signal can either go through the extrinsic pathway 
via direct cleavage of the effector caspase-3, alternatively, Bid is cleaved and its truncated bi-
product (tBID) can translocate to the mitochondria triggering the intrinsic pathway of 
apoptosis ultimately cleaving caspase-9 which in turn cleaves caspase-3 resulting in cell death 
[93]. In addition to TRAIL-R1 and -R2, TRAIL can bind to two additional receptors that 
either lack or have non-signaling, truncated intracellular domains. Decoy receptor (DcR) 1 
and 2 bind to TRAIL with high affinity but are unable to propagate an apoptotic signal [94, 
95]. Targeting of tumor cells by TRAIL-induced killing is a promising concept due to the 
constitutive expression of TRAIL-R1 and -R2 in many tumor tissues and the fact that DcR1 
and DcR2 are more frequently expressed in healthy tissue compared to transformed tissue 
indicating a low risk of toxicity [96]. FasL-mediated lysis of virus-infected or cancerous 
target cells is employed by both NK cells and T cells by binding to the single receptor FAS8
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triggering intracellular caspase-8 activation in a similar fashion as TRAIL-induced signaling 
[97, 98]. Moreover, NK cells and CTLs have the ability to secrete soluble FasL to induce 
caspase-dependent apoptosis in target cells. FAS is also expressed on activated lymphocytes 
enabling homeostatic regulation of immune responses by FasL-mediated elimination of 
lymphocytes [99]. Moreover, tumor cells can take advantage of this sensitivity by shedding 
FasL from the cell surface thus counteracting the anti-tumor response by killing the attacking 
lymphocytes [100, 101]. An example of the bridging between the innate and adaptive immune 
system is the killing of target cells that have been opsonized by antigen-specific antibodies by 
cells of the innate immune system such as monocytes, neutrophils and NK cells [102]. NK 
cells express only the high affinity Fcγ-receptor CD16 and not the lower affinity Fcγ-
receptors CD64 and CD32 nor the inhibitory Fcγ-receptor CD32b, and they have been shown 
to be one of the main cell types that contribute to the ADCC effect in cancer patients treated 
with monoclonal antibodies such as trastuzumab [103, 104].  
Figure 1. NK cell recognition of tumor cells. The cytolytic machinery of NK cells is controlled by 
a balance of activating and inhibitory signals received from interactions with their target 
cells. When NK cells interact with normal cells, which express both inhibitory receptors as well 
as low levels of activating receptors, the net sum of signals received by the NK cells triggers 
inhibition of the NK cells and the normal cell is spared. During malignant transformation, tumor 
cells often lose some or all of their MHC class I expression (missing self) while stress-induced 
activating ligands are upregulated. As a consequence, NK cells interacting with tumor cells 
receive enough activating signals to overcome the weak inhibitory signal by MHC class I 
leading to NK cell activation and lysis of the target cell by degranulation of perforin and 
granzymes or death receptor ligation. Opsonization of target cells with tumor antigen-specific 
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antibodies may also contribute to the activation of NK cells through interaction with Fcγ-
receptors in a process called antibody-dependent cell-mediated cytotoxicity (ADCC).     
1.2.4    Regulation of NK cell migration 
In order for NK cells to efficiently take part in immunosurveillance they need to be motile and 
in constant surveillance of the peripheral organs [105]. NK cells express a wide range of 
receptors that can induce chemotaxis to several different tissues. During pregnancy, 
trafficking of NK cells to the uterus is induced through recruitment via CCR2 and CCR5 
[106]. Under steady-state conditions CCR7+CD62L+CD56+ NK cells can be found in 
peripheral lymph nodes [107] and under inflammatory conditions NK cells can be recruited 
by DCs via CXCR3-induced migration to spleen and lymph nodes where they secrete high 
levels of IFNγ and engage in reciprocal interactions with DCs [108, 109]. This recruitment 
leads to maturation of both NK cells and DCs thus aiding in priming of T cells and TH1-
polarization [110-113]. Similarly, NK cells, which are among the first immune cells to appear 
at inflamed tissues, have the ability to secrete the CCL3, -4 and -5 enabling them to recruit 
DCs and other immune cells expressing CCR1 and CCR5 to the site of inflammation [114].  
NK cells are known to home to and infiltrate various different cancers where they in several 
cases have been shown to influence the patient’s prognosis [115-117]. In viral infections as 
well as in tumor sites, high titers of both type I and type II IFNs induce secretion of the 
chemokines CXCL9, CXCL10 and CXCL11 [26]. These ligands are potent chemokines 
attracting CXCR3-positive NK cells towards solid tumors, which has been exemplified by 
Wendel et al in elegant mouse models [118]. CCR5 has also been implicated in homing of NK 
cells towards tumors where plasmacytoid dendritic cells (pDCs) have been shown to be the 
main source of chemokine secretion [119].  
1.3    Cancer 
Cancer is initiated with a single cell acquiring damage to its DNA. It happens due to a variety 
of both endogenous and exogenous factors. In metabolically active cells, reactive oxygen or 
nitrogen species are constantly formed which continually cause single strand breaks in our 
DNA. Also, there are countless environmental factors, such as exposure to chemicals (food) 
or UV-radiation, which can directly or indirectly compromise the integrity of our genome and 
cause DNA damage. This type of damage occurs frequently in our cells every day and in the 
majority of cases the damage is either repaired by the actions of enzymes that are solely 
responsible to maintain the genetic structure of the cells [120, 121]. Alternatively, the cell 
undergoes programmed cell death which is known as apoptosis [122, 123]. DNA damage can 
cause mutations affecting the very control mechanisms that regulate DNA repair or induction 
of apoptosis, for example in the so-called oncogenes or tumor-suppressor genes. These genes 
code for proteins that are directly involved in maintaining the defense mechanisms that 
prevent uncontrollable cell growth and when they are mutated the cell can start to acquire 
traits that send it on a slippery slope to becoming a cancerous cell. These traits have been 
categorized as the “hallmarks of cancer” including the ability to; sustain proliferative 
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signaling, evade growth suppressors, resist cell death, induce angiogenesis, enable 
replicative immortality and activate invasion and metastasis [124]. In recent years, as the 
knowledge about tumors cells and their interactions with neighboring cells has increased 
dramatically, the complexity of the tumor microenvironment has become more apparent. This 
has led to the addition of emerging hallmarks of cancer including deregulation of cellular 
energetics and importantly the ability of cancer cells to avoid immune destruction [125].  
On average, a cancer cell acquires around ten mutations that can generate tumor-specific 
antigenic peptides. Moreover, as the tumor develops and undergoes dedifferentiation tumor-
associated antigens can emerge. Both of these antigens can be presented by APCs to trigger 
an adaptive immune response against the tumor [126]. Despite this, tumors very rarely regress 
due to spontaneously induced immune responses [127, 128]. In the following chapters I will 
discuss why this is the case and how we can help the immune system to fight cancer.  
3.3.1    Anaplastic thyroid cancer 
The thyroid gland is an endocrine organ located behind the laryngeal prominence (”Adams 
apple”) where it lies protected behind a cartilage shield. The healthy thyroid is histologically 
composed of follicles where the thyroid hormones are stored in the form of thyroglobulin. 
Upon stimulation of thyroid-stimulating hormone (TSH) secreted from the anterior pituitary 
gland in the brain, the thyroid hormones are released into the blood stream to exert their 
actions which include regulation of heart rate, digestion, metabolic rate, etc. In addition to the 
hormones produced by follicular cells, parafollicular cells 9
There are several different subtypes of tumors that originate in the thyroid and they can have 
very different progression patterns as well as prognosis. The well-differentiated tumors 
include papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) which have 
a relatively low proliferation rate and rarely metastasize unless in advanced disease stages. 
PTC and FTC patients often respond to treatment with radioactive iodine and the prognosis is 
generally good. Poorly differentiated thyroid carcinoma (PDTC) represents the middle stage 
between the well-differentiated thyroid carcinomas and the undifferentiated anaplastic thyroid 
carcinoma (ATC) which is the most aggressive and lethal of the thyroid cancers. ATC can 
arise de novo although in most cases it develops due to a dedifferentiation of an existing PTC 
or FTC [
 produce and secrete calcitonin 
which is an important regulator of calcium uptake and bone metabolism.  
129, 130] (figure 2).  
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The frequency of ATC varies in different parts of the world, from 1.7 % in USA to 7.9 % in 
the Netherlands [131, 132]. ATC is a disease of the elderly (mean age of diagnosis is 55-65 
years) and it is more common in women than in men. Due to the aggressive nature of ATC, 
the prognosis for patients is very poor. A meta-analysis of clinical reports from 1949-2007 
including 1771 ATC patients revealed a median survival of only five months [133]. Upon 
diagnosis, ATC commonly presents with tracheal invasion and in more than 50% of all 
patients, distant metastasis to the lungs, bones and brain [134]. There are several traits of ATC 
that contribute to its rapid progression and lethality. Somatic mutations in several genes 
regulating angiogenesis, growth rate and cellular adhesion are commonly found in late stage 
ATC including p53, PI3KCA and β-catenin [133]. As of today, there are no curative 
treatments available for ATC.  
 
Figure 2. Progression of thyroid malignancy. Thyroid follicular cells can undergo genetic 
changes that transform them into different tumor types. Follicular adenoma is characterized 
by follicular cell dedifferentiation and capsule formation. Upon invasion or penetration of the 
capsule the tumor is considered a follicular thyroid carcinoma. The papillary thyroid 
carcinomas are characterized by morphological changes in the follicular cells with an 
optically clear appearance or so called “orphan Annie nuclei” as well as the formation of 
tree-like papillae. When the cancerous cells accumulate mutations in p53, PI3KCA and β-
catenin, they can undergo extensive dedifferentiation leading to development of poorly 
differentiated anaplastic thyroid carcinoma. Here, the cellular morphology is heterogeneous 
within the tumor including squamoid, spindle cell and giant multinucleated cells and the 
growth pattern is invasive extending to vessels and extrathyroidal structures. In many of the 
undifferentiated thyroid carcinomas, there are areas of well-differentiated thyroid tumor 
indicating that they have de-differentiated from a pre-existing well-differentiated cancer.    
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1.3.1    The tumor microenvironment 
As tumor cells proliferate and start to form a tumor mass, the environment around it will be 
sculpted to aid the tumor as it grows. Tumor cells communicate through paracrine signaling 
with surrounding cells, creating a dynamic equilibrium that favors tumor progression. 
Mesenchymal stromal cells such as fibroblasts and pericytes are commonly transformed by 
tumors to promote tumor growth and metastasis via secretion of growth factors like fibroblast 
growth factor (FGF) or stromal-derived factor (SDF)-1α. [135-138]. The emergence or 
recruitment of cancer-associated fibroblasts (CAFs) in the tumor microenvironment is an 
important step in tumor development as they promote both tumor angiogenesis through 
production of vascular endothelial growth factor (VEGF) as well as tumor growth and 
metastasis through protease-mediated degradation of the extracellular matrix (ECM) [139, 
140]. Due to the chaotic structure of the neovasculature in rapidly growing tumors the oxygen 
levels are highly unstable and hypoxic regions commonly develop influencing several aspects 
of tumor growth including altered metabolic conditions as well as the differentiation and 
activity of CAFs [141, 142]. Hypoxia affects many immune cells including NK cells which 
under hypoxic conditions lose the ability to upregulate activating receptors in response to 
cytokine stimulation [143]. NK cells are highly influenced by cells and cytokines produced in 
the tumor microenvironment. In non-small cell lung cancer (NSCLC) the phenotype of 
intratumoral NK cells was modified showing reduced expression of NKp30, DNAM-1, 
NKG2D and CD16 compared to NK cells in the patient’s blood [144]. Tumors and tumor 
infiltrating myeloid and granulocytic cells have been shown to produce large amounts of 
reactive oxygen species (ROS) which is an essential part of these cells natural effector 
mechanism against pathogens. In physiological concentrations, ROS is beneficial for NK and 
T cells function but at high concentrations ROS can induce loss of function and even 
apoptosis of NK cells and other lymphocyte subsets due to induction of oxidative stress [145-
150]. Taken together, the tumor microenvironment can with time develop into a very hostile 
site for lymphocytes to operate in. However, it was recently reported that tumor cells and 
tumor-associated stromal cells were able to activate infiltrating NK cells in the 
microenvironment via trans-presentation of IL-15. The activated NK cells released large 
amounts of cytotoxic granules which resulted in eradication of large solid tumors. [151]. 
1.3.2   Immune surveillance of tumors 
The role of the immune system in surveillance of emerging tumors is underpinned by the 
finding that patients undergoing organ transplantation who are immunosuppressed for long 
periods of time have a greatly increased risk of developing tumors [152-155]. The risk is 
higher for developing tumors driven by oncogenic viruses such as human papilloma virus 
(HPV), hepatitis B and C virus (HBV/HCV) and Epstein-Barr virus (EBV) but is also seen for 
tumors that are not linked to viral oncogenesis [155]. Engel and colleagues established mouse 
models where methylcholanthrene (MCA)-induced tumors develop faster in 
immunocompetent mice compared with immunodeficient nude or severe combined 
immunodeficiency (SCID) mice [156, 157] thus arguing for immunosurveillance of 
chemically-induced tumors. The impact of NK cells in protection against tumors was 
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highlighted in a mouse model where NK cells in BALB/c mice were selectively depleted 
using the anti-asialo-GM antibody. Mice with functional NK cells had improved protection 
from MCA-induced fibrosarcoma compared with NK cell-depleted mice [158]. 
1.3.3   Tumor immunoediting 
As developing tumors are infiltrated and attacked by immune cells, the composition of the 
tumor is edited over time and is classically divided into three phases; elimination, equilibrium 
and escape (figure 3). In the elimination phase the tumor is at its most immunogenic. Innate 
immune cells recognize and target tumor cells expressing ligands for TRAIL, NKG2D, FasL 
etc. allowing for both direct and perforin-dependent cytolytic activity. Tumor cells present 
tumor antigens on MHC class I molecules that, together with a rich cytokine environment 
(high in type I and type II IFNs), supports recruitment of additional lymphocyte populations 
and aides in DC cross-presentation of tumor antigens to CD8+ T cells [159]. Macrophages of 
the M1 phenotype are important in the early stages of the elimination phase to secrete pro-
inflammatory cytokines such as TNFα, IL-12 and IL-1 that further boosts the activation of 
infiltrating immune cells and killing of the tumor. During the elimination phase, many tumor 
cells die by apoptosis but also from necrosis which in turn further stimulates the immune 
response by release of danger-associated molecular patterns (DAMPs) including high-
mobility group protein B1 (HMGB1) [160].  
When the anti-tumor immune response enters the equilibrium phase, there has been a 
selection of less immunogenic tumor cells that are not accessible or recognizable to the host’s 
immune system. Here, both adaptive and innate immune cells keeps the tumor growth in 
check and prevents both outgrowth and metastasis of tumor cells while at the same time 
sculpting the tumor to become more and more immune-resistant. The equilibrium phase can 
last the entire lifespan of the host. An example of a long equilibrium phase was the case of a 
woman with polycystic disease who received a kidney transplant from a donor that had been 
diagnosed, treated and “cured” of melanoma 16 years prior to the transplantation. When the 
kidney was transferred to a new host, the melanoma tumor cells in the kidney that had been 
under control of the donors immune system, now reemerged and subsequently killed the 
recipient [161].  
The constant immunological pressure on a tumor creates a darwinistic selection of the least 
immunogenic tumor cells. In the event that tumor cells alter their phenotype to the point that 
they can avoid recognition by the immune cells, the tumor can escape the immune control, 
progress and disseminate. Tumor cells can escape immune cell attack by different 
mechanisms. Firstly, they avoid recognition by CTLs either by shedding tumor antigens or 
alternatively by interfering with processing of antigens or downregulation of MHC class I on 
the cell surface [53, 162]. Moreover, tumor cells may downregulate or shed ligands for 
activating NK cell receptors, thus avoiding recognition by NK cells and inducing inhibition or 
even lysis of the NK cells or other lymphocytes [163-167]. In patients with colorectal cancer, 
NK cells has been shown to have lowered expression of both NKG2D as well as NKp44, 
CCR7 and CXCR1 due to high serum levels of soluble MICA and MICB molecules [168]. 
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Secondly, tumor cells can develop a resistance to lysis by immune cells either by upregulating 
anti-apoptotic proteins such as Bcl-2 and cellular FLICE inhibitory protein (cFLIP) [169-171]. 
Thirdly, tumors can create a surrounding milieu that is immunosuppressive and which 
converts and skews the resident immune cell population to a more immunoregulatory 
phenotype [172]. Myeloid-derived suppressor cells (MDSCs) are frequently found in the 
tumor microenvironment and they are often induced by tumor-derived factors including 
prostaglandin-E2 (PGE2) and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
[173-177]. The activation of MDSCs is often triggered by cytokines such as IFNγ and 
transforming growth factor beta (TGFβ), secreted from infiltrating T cells or tumor stroma 
[178, 179]. Several studies have shown that MDSCs are able to suppress both cytokine 
secretion and cytotoxicity of NK cells through production of PGE2 and ROS as well as 
through cell-cell interactions [174, 180-182]. However, in mice bearing B16 melanoma 
tumors, treatment with polyinosinic-polycytidylic acid (poly I:C) induced production of IFNα 
by MDSCs which mediated activation of NK cells and subsequent growth retardation of the 
B16 tumors[183]. 
Regulatory T cells (TREG ) are defined as CD4+CD25+CD127low/neg and express the forkhead 
box P3 (FoxP3) transcription factor [184]. They are important regulators of peripheral 
tolerance that can either delete or induce anergy in autoreactive effector T cells [185]. 
However, TREG are often induced or recruited to the tumor microenvironment where they can 
hamper the anti-tumor immune response [186, 187]. The effect of TREG on NK cells has been 
studied in mouse models where depletion of TREG augmented NK cell clearance of tumors 
while adoptive transfer of TREG inhibited NK cell activity and favored tumor progression 
[188, 189]. TREG can either inhibit NK cells activity by secretion of soluble TGFβ or ligation 
with membrane bound TGFβ [190], although a major mechanism of TREG-mediated 
suppression is to act as a cytokine sink10
191
 for IL-2 produced by CD4+ T helper cells thus 
depriving NK cells of one of their main activating cytokines [ ]. 
 
                                               
 
10 The cytokine sink effect is a term to describe how a cell type by depleting one or several cytokines in their 
environment will deleteriously effect other cell types that rely on stimulation by that particular cytokine.  
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Figure 3. Tumor immunoediting. When a tumor is subjected to an immune response, it can 
undergo three stages of immunoediting. During the elimination phase, the immunogenic 
tumor cells which express strong tumor-antigens on their cell surface and high levels of stress-
induced activating ligands, stimulate the priming of tumor-specific CTLs and are recognizable 
by innate immune cells.  During the equilibrium phase, the most immunogenic tumor cells 
have been eliminated and the tumor is under control by the immune system. If the least 
immunogenic tumor cells are able to avoid immune recognition and start proliferating, the 
immune escape phase is initiated. Here, the immune system no longer has the strength nor 
the specificity to target the expanding tumor, leading to uncontrolled growth and 
dissemination of the tumor  
1.3.4    Immune therapy of cancer 
The idea of utilizing the potential strength and specificity of the immune system to treat 
cancer has been around for many decades although it has been met with a great deal of 
skepticism over the years. It is not until in recent years, with the evidence of curative 
treatments of cancer patients using adoptively transferred tumor-specific T cells and the large 
scale randomized clinical trials with monoclonal antibody treatments that the field of cancer 
immunotherapy is really starting to gain traction. 
1.3.4.1    Cancer vaccines 
While prophylactic cancer vaccines targeting oncogenic viruses has reduced the incidence of 
cervical and other cancers dramatically worldwide, the struggle to decipher the clue to 
efficient therapeutic cancer vaccination continues [192]. The idea of cancer vaccination is to 
induce both a therapeutically effective immune response that can combat the existing cancer 
and to establish protective immunity to prevent tumor relapse [193]. Several approaches has 
been tested to achieve these goals including vaccination with autologous or allogeneic tumor, 
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either as a lysate or as whole tumor cells, peptides mimicking tumor specific epitopes, DNA 
encoding tumor antigen or DCs pulsed with either of the above [194-197]. Specific humoral 
and cellular responses have been detected in animal models as well as in patients but the 
clinical success have so far been poor [198]. Cancer vaccination relies on powerful adjuvants 
to aid the host’s resident APCs to take up and present the often weak tumor antigens that are 
injected [199]. In DC vaccination strategies, DCs are both loaded with antigen and matured 
under controlled conditions ex vivo ensuring potent interaction with the naïve immune system 
once injected to the patient [200]. In 2010, Provenge was approved by the food and drug 
administration (FDA). It is a DC vaccine targeting the prostate-specific antigen prostatic acid 
phosphatase (PAP) fused with GM-CSF. Phase III clinical trials have shown the 3-year 
survival improved by 40 % [201]. 
1.3.4.2    Checkpoint blockade 
T cells require two signals from APCs to become fully activated. The first is the T cell 
receptor interaction with the antigen presented on MHC molecules. The second signal is 
delivered by the co-stimulatory molecules CD8011 and CD8612
202-204
 expressed on DCs when they 
interact with CD28 on the T cells [ ]. Whereas the CD28 receptor triggers activation of 
the T cell, the cytotoxic T lymphocyte antigen 4 (CTLA-4) receptor, which is upregulated 
after priming of the T cell, is able to transmit an inhibitory signal that prevents over-activation 
of the T cell [205]. The development of monoclonal antibodies targeting CTLA-4 
(ipilimumab) has resulted in many clinical trials where its efficacy has been greatest in 
patients with metastatic melanoma [206, 207]. Moreover, CTLA-4 is constitutively expressed 
on TREG and part of the clinical effect of anti-CTLA-4 treatment in cancer patients is through 
in vivo abrogation of TREG function [208]. Programmed cell death protein 1 (PD-1) is another 
regulatory receptor expressed on T cells after antigen priming, although it is also expressed on 
NK cells, B cells and on myeloid cell subsets [209]. Upon ligation with its ligands PD-L1 and 
PD-L2 on target cells in the tumor microenvironment, the PD-1 receptor conveys an 
inhibitory signal to the T cells thus acting as a regulator of peripheral tolerance [210]. 
Antibody blockade of PD-1 (nivolumab) and PD-L1 has been tested in clinical trials where it 
has been shown to be safe and has generated objective responses in patients with NSCLC, 
renal cell carcinoma (RCC) and melanoma [211, 212]. Since anti-CTLA-4 and anti-PD-1 
respectively controls the immune checkpoints of both central and peripheral tolerance, the 
prospect of combining the two treatments could potentially act in synergy to augment both 
priming and activation of T cells against their tumor targets.  
                                               
 
11 B7-1 
12 B7-2 
 
31 
1.3.4.3    T cell therapy 
The idea of adoptive cell transfer is to extract lymphocytes from a cancer patient, manipulate 
and expand the cells ex vivo and finally reinfuse them to the patient. The T cells are isolated 
either from peripheral blood or from infiltrating lymphocytes in the patient’s tumor. When 
isolating tumor-infiltrating lymphocytes (TILs) from a naturally immunogenic tumor such as 
melanoma, the chances of finding T cells with specificity against a tumor-antigen is high. By 
removing the tumor-reactive T cells from the suppressive tumor microenvironment and 
culturing them in stimulatory cytokines such as IL-2, it alleviates the inhibition from 
immunosuppressive cytokines, immunoregulatory cells and PD-1 and CTLA-4 blockade, 
allowing the T cells to proliferate to large numbers. To further augment the specificity of the 
T cell product, some protocols employ purification and cloning of antigen-specific TILs 
before starting the ex vivo expansion [213]. Melanoma tumor cells normally expresses high 
levels of melanocyte differentiation antigens (MDAs) for which specific T cells can be 
isolated and expanded for adoptive TIL therapy. Targeting of a tissue-specific differentiation 
antigen often generates off-target toxicity to normal cells expressing that same antigen [214]. 
Melanoma patients treated with TILs against MDAs have suffered from adverse events such 
as vitiligo, partial blindness and deafness [215-217]. Because of the inherent genetic 
instability of melanoma and other tumors, there have been several antigens described that are 
truly tumor-specific in the sense that they are products of mutated genes [218]. These tumor-
antigens as well as oncogenic viral antigens often drive the cancer progression and are easily 
targeted by T cell since they have not been tolerized to the antigens in the thymus [219]. 
The strength of the anti-tumor effect of adoptively transferred tumor-specific T cell can vary 
between each patient and the purely cytolytic effect is mediated via both release of toxic 
granules but also by death ligand-induced apoptosis. However, the T cells that home to the 
tumor site (including both CD8+ and CD4+ T cells) are also potent producers of both 
chemokines and cytokines such as TNFα and IFNγ. Tissue resident DCs respond to the 
cytokine stimulation by upregulating their expression of MHC class I and MHC class II which 
together with CD4+ T cell cross-talk leads to increased recruitment and activation of NK cells 
and other innate immune cells [220]. There are several barriers that limit the large-scale use of 
adoptive cell therapy. Firstly, to achieve long-term persistence and boost the anti-tumor effect 
of the infused lymphocytes, the patients are required to undergo heavy preconditioning prior 
to the adoptive transfer. To make space for the infused cells and avoid the cytokine sink effect 
as well as to eliminate immunosuppressive lymphocyte subsets, patients receive lympho-
depleting chemotherapy, which can be supplemented with directed or total body irradiation 
[221]. This regimen together with high dose adjuvant IL-2 treatment, to maintain proliferation 
of lymphocytes in vivo, reduces the inclusion criteria to patients with good performance status 
[222, 223]. Secondly, isolation of strong tumor-antigen reactive T cells from a biopsy is not 
possible for all patients, nor is the ability to generate the large numbers of T cells that are 
required for lymphocyte infusion. Thirdly, isolation and expansion of the lymphocyte product 
ex vivo is an extremely laborious and expensive process that requires specialized good 
manufacturing practice (GMP) facilities. However, when adoptive treatment of TILs is 
successful, the clinical responses can be dramatic. In three sequential clinical trials where a 
 
32 
total of 93 patients with metastatic melanoma were treated with autologous TILs and IL-2, the 
objective response rate ranged between 49% to 72% and complete regression of the tumor 
was achieved in 22% of the patients [224]. In recent years, the development of chimeric 
antigen receptors (CARs), with increasingly stronger intracellular signaling capacity, has 
sparked the interest in using genetically modified T cells to treat cancers that are otherwise 
difficult to target with conventional T cells [225]. Retargeting T cell lysis against a particular 
cancer-related molecule (including antigens other than proteins) in a non-MHC-restricted 
manner has led to efficient targeting of leukemias by CD19- and CD20-CARs and NY-ESO-
1-CARs in multiple myeloma (MM) and several other cancer types [226-228]. 
1.3.4.4    NK cell therapy 
The NK cell is a promising cell type to utilize for adoptive cell therapy due to several 
different reasons. They do not require priming or prior sensitization to interact with and kill 
tumor cells, they can be isolated directly from peripheral blood from both patients and healthy 
donors and they can be expanded and genetically modified ex vivo (figure 4). 
1.3.4.4.1 NK cell therapy against hematological tumors  
The first truly potent clinical effect of NK cells against cancer was demonstrated when 
Ruggeri and colleagues transplanted patients suffering from acute myelogenous leukemia 
(AML) with T cell depleted KIR-ligand mismatched bone marrow transplantation (BMT) 
[229]. The patients receiving grafts with KIR-ligand incompatibility had 60% probability of 
event-free survival after 5 years compared to 5 % in the patients receiving KIR-ligand 
compatible grafts. Moreover, the incidence of graft-versus-host disease (GVHD) was also 
lower in patients receiving KIR-mismatched BMT. The authors hypothesized that the 
contribution of the alloreactive NK cells in the graft was three-fold. Firstly, the NK cells 
target the residual leukemic blasts, thus preventing disease relapse. Secondly, NK cell-
mediated elimination of recipient APCs prevents their presentation of host-antigen to donor 
derived T cells thus reducing the risk of GVHD. Thirdly, by targeting the residual recipient T 
cells, the NK cells promote the engraftment of the BMT [230, 231]. There are numerous 
recent and ongoing clinical trials in patients with different hematological tumors that assess 
the importance of donor selection based on KIR/HLA phenotype of NK cells both in the 
setting of NK cell adoptive therapy or as an adjunct to hematopoietic stem cell transplantation 
(HSCT) [232, 233]. Miller et al. showed in 2005 that adoptive transfer of haploidentical NK 
cells was safe and mediated anti-tumor effect in lymphodepleted AML patients receiving 
daily low-dose injections of IL-2 [233]. Persistence of NK cells was higher in patients 
receiving preconditioning and correlated with in vivo expansion and clearance of leukemia.  
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Figure 4. Isolation and expansion of NK cells for adoptive transfer. Peripheral blood 
mononuclear cells (PBMCs) are cells purified from peripheral blood of a cancer patient and 
the NK cells are isolated using CD56-specific magnetic bead selection. In order to obtain high 
numbers of cytotoxic NK cells, the isolated NK cells are cultured in the presence of high doses 
of NK cell-stimulatory cytokines such as IL-2 and an irradiated feeder cell population. The 
expansion phase can take up to several weeks and meanwhile the patient can undergo 
preconditioning to make space for the infused cellular product as well as to sensitize the 
patients tumor to NK cell lysis. The expanded NK cells have a high proliferation rate (after two 
weeks of expansion the NK cells can expand up to 1000-fold), high expression of activating 
receptor resulting in high cytotoxicity and elevated expression of chemokine receptors 
allowing them to home toward chemokines secreted from tumors. The expanded NK cell 
product is infused to the patient intravenously in bolus doses of up to 1x 108 NK cells/kg of 
recipient body weight.  
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1.3.4.4.2 NK cell targeting of solid tumors 
Although the anti-tumor effect of NK cells in vivo has been demonstrated in several 
hematological malignancies, the use of NK cells in treatment of solid tumors has yet to show 
clinical benefit [234-236]. There are several explanations for the difficulty of targeting solid 
tumors. Firstly, cells that form solid tumors have the advantage of creating a tumor 
microenvironment that is suppressive towards NK cells, where the actions of TREG and 
MDSCs play a major role. Therefore, adoptively transferred NK cells must have properties 
allowing them to withstand 1) inhibition by suppressive cytokines and cells, 2) a hostile and 
often hypoxic microenvironment and 3) direct cytotoxic counteractive measures employed by 
the tumor cells and associated cells [237]. Secondly, tumor cells that undergo immune editing 
often downmodulate their expression of ligands that are targetable by NK cell receptors [238, 
239]. Thus, it is difficult for NK cells to recognize and destroy immune escape variants of 
cancer cells. This highlights the need for pre-sensitization of established tumors to NK cell 
lysis, as well as identification of predictive markers for NK cell therapy (discussed in paper I 
and IV). Also, NK cells may need to be pre-treated or ex vivo expanded in different fashions 
depending on the nature of the tumor that they are intended to target (discussed in paper II). 
Thirdly, only a fraction of all adoptively transferred NK cells actually reach the tumor site 
[240]. Expression of the appropriate chemokine receptors on the infused NK cells as well as 
induction of chemokine secretion from tumors or tumor-associated cells is essential for 
efficient recruitment of NK cells to the tumor site where they can elicit their tumoricidal 
effect (discussed in paper III). 
 1.3.4.4.3 Cytokine-induced activation of NK cells 
NK cells depend on cytokine stimulation for their function and survival. IL-2 has for many 
years been used to stimulate NK cells ex vivo and has been given to patients with cancer for 
several decades showing clinical responses both as a single therapy, in combination with 
cancer vaccines or in adoptive cell transfer [241, 242]. However, administration of high dose 
IL-2 is associated with severe toxicity such as capillary leak syndrome and other symptoms 
[243]. So far, adjuvant IL-2 treatment has generated in vivo proliferation and long-term 
persistence of adoptively transferred NK cells although the anti-tumor effect has been modest 
[236]. Therefore, additional NK-stimulating cytokines has been evaluated both for ex vivo 
manipulation and for in vivo use including those naturally derived from DCs. Depending on 
the subset of DC and what PAMPs they have engaged in the periphery, DCs can induce 
different types of activation signals for NK cells by either secreting or presenting cytokines to 
NK cells in SLOs [244]. IL-12 and IL-18 is secreted to activate and induce secretion of 
cytokines by NK cells, IL-15 is trans-presented by DCs to induce proliferation and provide 
survival signals to NK cells while type I IFNs can induce NK cell cytotoxicity [245-248]. 
Presumably, culturing of NK cells in a combination of cytokines prior to infusion would be a 
good strategy to allow for persistence and cytotoxicity in vivo. In a recent study, Cerwenka 
and colleagues found that in mice bearing solid tumors, administration of NK cells pretreated 
with a cocktail of IL-12, IL-15 and IL-18, in combination with radiotherapy, was superior in 
delaying tumor growth compared to IL-15-treated NK cells plus radiotherapy or radiotherapy 
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alone [249]. The IL-12/15/18-primed NK cells displayed properties that resemble “memory-
like” NK cells including high proliferative capacity and in vivo persistence. Moreover, the 
traits were retained over several generations of NK cells [250]. The importance in IL-15 
stimulation of NK cells has also been demonstrated by Szczepanski and colleagues who has 
shown that the cytotoxic potential of suppressed NK cells from AML patients could be 
restored ex vivo by exposure to IL-15 [251].  
1.3.4.4.3    Ex vivo expansion and genetic modification of NK cells 
There have been different opinions on the pros and cons and the potential benefit of ex vivo 
expansion of NK cells prior to infusion [252]. Preparation of the cellular product from 
peripheral blood mononuclear cells (PBMCs) is done by different variations of magnetic bead 
selection under GMP-conditions where the CliniMACS system (Miltenyi) is currently the 
only system approved by the FDA to be used in clinical trials. In an autologous setting, 
contamination of T cells is generally acceptable while in an allogeneic setting, a depletion of 
T cells using anti-CD3 magnetic beads is required to prevent induction of GVHD. After CD3 
depletion the product still contains large amounts of monocytes and B cells and a second step 
of CD56+ cell magnetic bead selection can be employed, usually yielding a more than 99% 
purity of NK cells [253, 254]. By expanding the NK cell population using feeder cell 
populations, the fold expansion of NK cells can be increased compared to using only 
cytokines. A larger absolute number of NK cells in the infused cell product could increase the 
chances of targeting cancer cells, although the risk of encountering replicative senescence is a 
factor to consider, as it has been shown with TILs that a shorter activation regimen ex vivo 
allows for higher in vivo proliferation [255].  
When choosing the method for ex vivo activation it is also important to consider the selective 
expansion of certain NK cell subsets and the effect of the particular protocol on phenotype 
and function of the NK cells. Although cytokine stimulation with IL-2 has shown nearly 200-
fold expansion rates of NK cells, culturing of NK cells with the MHC-class I deficient 
leukemic cell line K562 expressing 41BB-ligand and IL-15 provided stimulation and trans-
presentation of IL-15 that induced proliferation of NK cells up to 1000-fold expansion, with 
increased cytotoxicity and IFNγ secretion [256, 257]. Similar proliferative capacity was 
observed when NK cells were cultured with irradiated EBV-transformed B cell lines which 
also augmented NK cell killing of tumors with marked upregulation of TRAIL, FasL and 
NKG2D [258]. Although the field of genetic modification of NK cells is struggling with low 
transductions rates, NK cells have been successful transduced with a CD19-specific CAR 
with a CD3 ζ-chain which improved the NK cells killing capacity against CD19-positive 
leukemia cells [256].  The NK cell line NK92 has also been successfully transduced with a 
HER2/NEU-CAR inducing cytotoxicity against a HER2/NEU positive cell line that was 
completely resistant to untransduced NK92 cells [259]. 
1.3.4.4.4    Reducing suppression of NK cells 
TREG have a strong inhibitory effect on NK cells and in combination with IL-2 treatment of 
patients undergoing NK cell transfer, TREG are generated and preferentially activated thus 
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contributing both to immune suppression of NK cells and to a cytokine sink effect [260, 261]. 
A recent study showed that, in a BALB/c mouse model, administration of IL-2 diphteria toxin 
prior to adoptive transfer of syngeneic IL-15-treated NK cells, selectively depleted TREG and 
resulted in NK cell mediated boosting of adaptive immune responses, reduced tumor 
clearance and increased survival [262]. As described earlier, MDSCs are potent inhibitors of 
NK cell function. Efforts to limit the conversion of myeloid cells into MDSCs and to inhibit 
their actions have recently shown beneficial effects in mouse models of cancer. By 
administration of nitro aspirin and the phosphodiesterase 5 inhibitor Sildenafil in mice, 
inducible nitric oxide synthase (iNOS) and arginase I (Arg1) production in MDSCs is reduced 
respectively, resulting in MDSCs displaying a less suppressive phenotype and increased 
tumor infiltration and efficacy of adoptively transferred T cells in tumor bearing mice [263-
265]. However, none of the treatments resulted in decreased tumor progression. By treating 
mice as well as humans with either cyclooxygenase 2 (COX-2) inhibitors, reduced levels and 
reduced suppressive capacity of MDSCs has been observed [174, 266].  
1.3.4.4.5    Improving homing of NK cells towards tumors 
Studies on the recruitment of lymphocytes to tumor sites have mostly been performed in the 
context of CTL [267]. There has been evidence of tumor infiltration of adoptively transferred 
melanoma-associated antigen recognized by T cells (MART-1)-specific T cells in melanoma 
patients where up to 38% of infiltrating T cells were MART-1 specific but also in MART-1 
expressing non-malignant tissues leading to vitiligo [268]. Although there little known about 
the rate of tumor infiltration and quantification of absolute numbers of adoptively transferred 
cells, one study showed that only 0.016 % of the total number of infused cells in a patient 
with melanoma was localized per gram of tumor [240]. This finding together with 
observations of tumor progression despite high levels of circulating tumor-antigen specific T 
cells after adoptive transfer highlight the importance of efficient lymphocyte homing to 
achieve a clinical response [269]. In mouse models it has been shown that transduction of 
tumors with the chemokine CCL21 resulted in increased cytotoxic activity of adoptively 
transferred T cells and prolonged survival in the mice although increased T cell infiltration 
could not be detected [270]. In other studies, introduction of chemokine genes such as CCL3 
and XCL1 induced migration of T cells to the tumor site but failed to induce tumor regression 
[271]. In another model, tumors adenovirally transduced with CX3CL1 had increased 
accumulation of both T cells and NK cells which contributed to suppression of tumor growth. 
Expression of CX3CL1 as well as CXCL10 in tumor tissues has been shown to be one of the 
main predictive factors for infiltration of CTLs in colorectal cancer, although the correlation 
did not apply to tumor infiltration of NK cells [29]. However, CX3CL1 receptor CX3CR113
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has been shown to be a major governing chemokine receptor for successful homing of NK 
cells to the central nervous system during experimental autoimmune encephalomyelitis and 
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induction of CX3CL1 in murine lymphoma cell lines induced NK cell recruitment and 
inhibition of tumor development which was abrogated in RAG-/- mice14
272
 suggesting that NK 
cells play a major role in the anti-tumor effect [ ].  
Expression of the relevant chemokine receptors is essential for the induction of homing of 
lymphocytes towards tumors. Genetic manipulation of the infused cell product as a strategy to 
augment the chemokine receptor expression and induce tumor-directed migration has been 
shown to be beneficial in mouse models. Peng and colleagues introduced the CXCR2 gene in 
pMEL-1 T cells recognizing the gp100 peptide on melanoma cells. The melanoma cells 
spontaneously produce the CXCL1 and CXCL8 chemokines that ligate and attract CXCR2 
positive lymphocytes. Adoptively transferred CXCR2-transduced T cells showed increased 
localization to the tumors resulting in reduced tumor progression and prolonged survival 
[273]. The importance of CXCR3-induced migration of NK cells towards tumors was 
demonstrated by Wendel et al. They showed in a mouse model that CXCR3-positive NK cells 
could home to and reduce the progression of tumors that ectopically express CXCR3-ligands 
or alternatively are treated with IFNγ to overexpress the ligands. In CXCR3-/- mice the 
accumulation of NK cells in the tumors was impaired [118].  
1.3.4.4.6    Combination therapies 
Chemotherapy agents are designed to kill human tumor cells while causing minimal toxicity 
to normal cells. However, the secondary effects that they may have in an immune competent 
host are rarely assessed before they are put to clinical use [274]. Although there is a risk that 
chemotherapy would induce a selection of tumor cells that are resistant to cellular stress and 
would therefore become resistant to both continued chemotherapy and immune cell attack, 
several studies has shown that many different chemotherapy agents can boost the anti-tumor 
immune response by several different mechanisms [275]. Induction of immunogenic cell 
death can be achieved by several pharmacological compounds. Anthracyclines and platinum-
based drugs have been shown to induce relocation of calreticulin to the cell surface, thus 
promoting phagocytosis and antigen presentation of tumor cell peptides. A second effect is 
the increased release of danger signals such as HMGB1 which binds the PPR toll-like 
receptor 4 (TLR-4) on DCs thus facilitating cross-presentation of the processed peptides [276, 
277].  
Enhancing the sensitivity of tumor cells to killing by lymphocytes by chemotherapy treatment 
has been demonstrated in several studies. By upregulating the tumor-antigen carcino-
embryogenic antigen (CEA) on colon and breast cancer cells, treatment of tumor cells with 5-
fluoracil enhanced their sensitivity to killing by HLA-A2 restricted T cells [278]. 
Upregulation of mannose-6-phophate receptors on tumor cells induced by the chemotherapy 
agents paclitaxel, cisplatin and doxorubicin enhanced the tumor cell’s permeability to 
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granzyme B making them sensitive to killing by tumor-specific T cells. This approach also 
induced a bystander effect when adjacent tumor cells that did not express tumor antigen were 
targeted by the cytotoxic effect of granzyme B released from the T cells [279]. The ligands for 
NKG2D are inducible by cellular stress and it has been shown that treatment of cell lines with 
proteasome inhibitors or histone deacetylase (HDAC) inhibitors upregulated expression of 
ULBP2, MICA and MICB on tumor cells [280]. In some studies, cell lines treated with 
HDAC inhibitors displayed increased sensitivity to lysis by NK cells [281, 282] which could 
be synergistically enhanced in combination with ionizing radiation [283]. Elevated sensitivity 
to NK cell lysis via upregulation of TRAIL-R2 has also been reported in cell lines and in mice 
treated with the proteasome inhibitor bortezomib [284, 285]. There have also been reports of 
radiotherapy regimens that augment immune responses [277, 286]. A study showed that in 
situ tumor destruction by radiofrequency ablation induced an immune response in a B16-
OVA melanoma model which was greatly enhanced in combination with anti-CTLA-4 
antibody treatment [287]. Chemotherapeutic agents often have immunosuppressive side 
effects where some of the more well known, including methotrexate and imatinib, have 
deleterious effect on peripheral T cells [288, 289] Although cyclophosphamide and 
fludarabine (Cy/Flu) are commonly used to lymphodeplete patients with leukemia or as a 
preconditioning to adoptive cell transfer, residual T cells after Cy/Flu treatment have a mature 
phenotype, are predominantly TH1 polarized and are more responsive to mitogen stimulation 
[290]. Moreover, Cy/Flu treatment as well as 5-fluoracil can aid anti-tumor immune responses 
by selectively depleting suppressive immune subsets [291-293]. Myeloid cells are particularly 
sensitive to chemotherapy agents although there are differences among drugs. At therapeutic 
concentrations, doxorubicin, cisplatin and vinblastine can easily trigger DC apoptosis while 
the toxicity of etoposide and 5-fluorouracil is relatively low [294]. Several targeted therapies 
are also found to work in concert with the immune system. By inhibiting VEGF, which has 
been shown to inhibit differentiation and maturation of DCs, the anti-VEGF monoclonal 
antibody bevacizumab or tyrosine kinase inhibitors sorafenib or sunitinib can restore function 
of tumor resident DCs while simultaneously inhibiting tumor vascularization [295]. In cancer 
patients receiving monoclonal antibody treatment such as cetuximab, which targets the 
epidermal growth factor, the ADCC effect by NK cells has been shown to contribute to the 
anti-tumor effect [296]. There has also been a correlation found between NK cell function and 
the response of trastuzumab in patients with metastatic breast cancer [103].  
Antibody-mediated blocking of NK cell inhibitory receptors has been tested in a mouse 
leukemia model where an antibody targeting the murine equivalent of KIR, the Ly49-
receptor, demonstrated anti-tumor effect with low toxicity [297]. Importantly, subsequent 
studies showed that long-term exposure to Ly49-targeting antibodies did not induce 
autoimmunity or NK cell anergy suggesting that NK cell licensing was not disrupted by the 
antibody treatment [298]. Moreover, combination of the immunostimulatory drugs 
lenalidomide with KIR-blocking antibodies has shown synergistic effect in a MM mouse 
model [299, 300]. A human antibody targeting KIR2DL1/2/3 augments NK cell lysis of MM 
and AML blasts in vitro and was shown to be tolerable in a phase I trial [301]. In clinical 
trials and in pre-clinical studies checkpoint inhibitors have been combined with each other as 
well as with other targeted therapies. Wolchok et al showed that concomitant treatment of 
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patients with advanced melanoma with ipilimumab and nivolumab resulted in that 53% of 
patients had objective tumor responses and 80% of the responders had tumor regression [302]. 
Ipilimumab has also been combined with autologous tumor lysate vaccination plus GM-CSF 
in patients with advanced ovarian carcinoma which generated clinical responses. Here, the 
extent of tumor necrosis correlated with an increased CTL/TREG ratio [303] indicating that 
CTLA-4-meditaed TREG-depletion by ipilimumab may have contributed to the specific CTL-
response. Although few, there have been reports of patients experiencing tumor regression of 
distant metastasis after directed radiotherapy to their primary tumors [304-306]. This 
phenomenon has been termed “abscopal effect” and provides striking evidence for how 
localized radiotherapy can induce immunogenicity of a tumor that is strong enough to elicit a 
systemic anti-tumor immune response [307]. It is known that when a tumor is subjected to 
ionizing radiation, several events occur that may promote both infiltration and tumor-
recognition by lymphocytes, including chemokine release, presentation of tumor-antigen and 
upregulation of death receptors and adhesion molecules [308-311].  
Considering the complexity and dynamic nature of the interactions between a tumor and the 
immune system, it is best to take a multimodal approach when designing immune therapeutic 
strategies against cancer. With increasing knowledge of how our most commonly used 
chemotherapeutic drugs and radiation regimens affect the phenotype of tumor cells and the 
micromileu of the tumor surroundings, their clinical use can be fine-tuned to work in synergy 
with the anti-tumor immune response. Furthermore, with the recent development of new 
immunomodulatory agents and targeted therapies against cancer we now have a better 
capability to tailor immune therapies to each individual cancer patient. For NK cell-based 
therapy, few cancer types have been tested in clinical trials and the use of combination 
treatments have not yet been evaluated extensively. Therefore, there are still many hurdles 
that need to be bridged for NK cells to reach their full therapeutic potential. In this thesis I 
have focused on three of them; low sensitivity of tumors to NK cell lysis, poor migration of 
NK cells toward solid tumors and lack of tumor targets that are prone to killing by NK cells.   
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2.    Aims of the thesis 
The general aims of this thesis is to increase the understanding of how NK cells interact with 
tumor cells with the overall purpose to bridge the hurdles that are currently facing NK cell-
based therapies. The thesis is divided into three parts and their respective aims are: 
1. Enhancing NK cell cytotoxicity towards tumor cells: exploring ways to enhance the 
anti-tumor effect of adoptively transferred NK cells, either by sensitizing tumor cells 
to NK cell mediated lysis or by boosting the cytotoxic potential of ex vivo expanded 
NK cells. (Paper I and II) 
 
2. Augmenting NK cell migration toward solid tumors: studying how chemokine-
induced migration of expanded NK cells affects their homing toward solid tumors and 
how it impacts the anti-tumor effect. (Paper III) 
 
3. Finding novel tumor targets for NK cell therapy: assessing the interaction between 
NK cells and anaplastic thyroid carcinoma cells in terms of mechanism of NK cell-
mediated lysis as well as chemoattraction and regulation of NK cell activity. (Paper 
IV). 
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3.    Results and Discussion 
3.1    Enhancing NK cell cytotoxicity against tumor cells 
In the past few decades, breakthroughs in technical development of cell culture systems, 
selection of donors and subsets of NK cells for infusion as well as improved GMP facilities, 
have increased the ability to treat cancer patients in a personalized setting with large amounts 
of ex vivo expanded NK cells. However, the inherent regulation of NK cell cytotoxicity is still 
a factor that needs to be considered when NK cells are infused and expected to find and kill a 
tumor. The inhibition of NK cells by MHC class I molecules as well as the downregulation or 
shedding of recognition receptors on tumor cells reduces the chances of generating an anti-
tumor effect by infused NK cells, even if the NK cells are able to reach and interact with the 
patient’s tumor. Two strategies to overcome the decreased targeting are to either sensitize 
tumor cells to NK cell lysis or to manipulate NK cells ex vivo to improve their targeted 
cytotoxicity. 
3.1.1    Paper I 
The aim of this paper was to study chemotherapy-induced sensitization of tumor cells to lysis 
by activated NK cells and T cells. The proteasome inhibitor bortezomib has previously been 
shown to render tumor cells sensitive to NK cell-mediated lysis [284]. However, due to the 
interference with antigen processing following bortezomib treatment, tumor cells were 
rendered almost completely resistant to lysis by tumor-specific T cells [312]. An appealing 
prospect in the field of adoptive cell transfer is to combine both NK cell- and T cell-infusions 
to increase the chances of targeting tumor immune escape variants. Therefore, we aimed to 
screen several different chemotherapy agents for their potential to induce sensitivity to both 
NK cell and T cell mediated lysis. We found that the chemotherapy agent doxorubicin15
313
, 
which had previously been described to induce sensitivity to lysis by recombinant TRAIL, 
could sensitize tumor cells to lysis by both ex vivo expanded NK cells and T cells expressing 
high levels of surface bound TRAIL (figure 5). Through blocking studies we could confirm 
that when TRAIL was blocked in co-cultures where NK cells or T cells were incubated with 
doxorubicin-treated tumor cells, the level of tumor cell lysis was significantly reduced. As 
previously described, we found that expression of the anti-apoptotic protein cFLIP in tumor 
cells was almost completely abolished already after a few hours incubation with subapoptotic 
levels of doxorubicin [ ]. cFLIP inhibits the cleavage of pro-caspase-8 into active caspase-
8 which subsequently cleaves effector caspases and ultimately induces apoptosis in the tumor 
cell. Alternatively, active caspase-8 can cleave Bid which propagates the apoptotic signal via 
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the mitochondrial pathway [314]. We observed that when tumor cells were exposed to low 
levels of doxorubicin or NK cells, we measured only minimal activation of caspase-8 and 
cleavage of Bid. However, if we added NK cells to a tumor cell culture that had been 
pretreated with doxorubicin, there was a marked increase in both activation of caspase-8 and 
Bid-cleavage, indicating a synergistic effect.  
Next, we assessed whether doxorubicin could sensitize tumors to adoptively transferred NK 
cells in a xenogeneic mouse model where immunodeficient mice bearing subcutaneous tumor 
received infusions of human expanded NK cells and/or tumor-specific T cells. Mice received 
intravenous injections of low levels of doxorubicin 24 h prior to the lymphocyte infusions. 
We observed that, while the doxorubicin treatment alone did not affect the tumor progression, 
it reduced the tumor progression in the mice that received NK cells, T cells or a combination 
of NK and T cells. Interestingly, in doxorubicin treated mice, the combination of NK and T 
cells generated the greatest anti-tumor effect when compared with infusions of NK cells alone 
or T cells alone. From our findings, we can conclude that doxorubicin has the potential to 
sensitize tumors to lysis by NK cells or T cells through increasing TRAIL-mediated signaling. 
Thus, doxorubicin could potentially be used as an adjuvant therapy for NK cell or T cell-
based adoptive transfer therapies. There have been other immune-related effects of 
doxorubicin that could synergize with the induction of NK cell sensitivity. By triggering 
immunogenic cell death, the chances of priming of tumor-specific T cell responses increases 
which could be further augmented by the tumor cells doxorubicin-induced sensitivity to 
TRAIL-mediated T cell lysis [276]. Recently, it has been shown that doxorubicin selectively 
depletes MDSCs and reduces MDSC suppressive function in mice thus augmenting 
degranulation of NK cells and CTLs in doxorubicin-treated mice. In humans, isolated MDSCs 
were sensitive to doxorubicin toxicity in vitro [315]. This reduction of immune suppression 
would further aid in the NK and T cell-mediated lysis of doxorubicin-treated tumors. 
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Figure 5. Doxorubicin sensitizes tumor cells to NK cell lysis via increased TRAIL-signaling. 
Doxorubicin has a dual effect in sensitizing tumor cells to lysis by expanded NK cells expressing 
high levels of TRAIL. When added to tumor cells at sub-apoptotic concentrations, doxorubicin 
induces cell surface expression of TRAIL-R2 which promotes binding of membrane-bound 
TRAIL. The ligation results in recruitment of pro-caspase-8 to the DISC complex which is 
cleaved into active caspase-8 resulting in initiation of an intracellular apoptotic cascade. The 
second effect of doxorubicin is the induced downregulation of the anti-apoptotic protein 
cFLIP in tumor cells. cFLIP inhibits the cleavage of pro-caspase-8, which in untreated cells 
abrogates the apoptotic cascade. Therefore, in doxorubicin-treated cells, both the 
TRAIL/TRAIL-R2 interaction as well as the intracellular TRAIL-signal is amplified leading to an 
increased sensitivity of the tumor cells to NK cell-mediated lysis. Signaling via TRAIL is 
described in detail on page 21.   
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3.1.2    Paper II 
In this paper we aimed to study the immunostimulatory effect of zoledronic acid (ZA) on 
human NK cells. ZA is used to treat cancer patients suffering from bone metastasis by 
preventing bone resorption thus reducing the risk of skeletal complications. Here we show 
that monocytes stimulated with ZA are stimulated to produce IFNγ. Selective expansion of γδ 
T cells16
316
 has been observed in PBMC cultures treated with ZA and IL-2 and ZA have also 
been shown to sensitize colon cancer cells to lysis by γδ T cells [ , 317]. ZA-treated DCs 
can in turn activate NK cells via production of IL-18 and IL-1β and NK cells can be further 
co-stimulated by ZA-activated γδ T cells [318]. We found that monocyte-derived IFNγ was 
responsible for the induction of TRAIL expression on NK cells (figure 6). When NK cells 
were co-cultured with monocyte-depleted PBMCs in presence of ZA, induction of TRAIL 
expression on NK cells was abolished. Indeed, co-culture of NK cells and purified monocytes 
provided an additional boost of TRAIL-expression on NK cells and also increased secretion 
of soluble TRAIL and FasL. NK cells primed with ZA in a monocyte co-culture also acquired 
an increased cytotoxic effect against TRAIL-sensitive tumor cell lines in vitro. The clinical 
significance of ZA as an immune stimulatory drug was demonstrated in an immunodeficient 
SCID/Beige mouse model, where infusion of ZA-primed NK cells reduced tumor progression 
and prolonged survival of tumor-bearing mice when compared with mice receiving unprimed 
NK cell infusions. In the clinic, a combined treatment with ZA and IL-2 in patients with 
metastatic prostate cancer has shown to be safe where treatable side effects have been 
attributable to the IL-2 treatment. Patients maintained high levels of soluble TRAIL produced 
largely by activated γδ T cells whose numbers correlated with clinical outcome [319]. Our 
study shows that ZA could be used both in combination with autologous monocyte cultures in 
the priming of NK cells prior to infusion in patients carrying TRAIL-R -positive tumors. 
Alternatively, patients could be pretreated with chemotherapy inducing sensitivity to TRAIL-
mediated lysis, including doxorubicin or the novel proteasome-inhibitor bAP-15 [320-322]. 
  
                                               
 
16 The γδ T cell is a relatively uncharacterised cell type which has properties resembling both 
innate and adaptive immune cells. It has a non MHC-restricted T cell receptor and they are 
most frequent in epithelial tissues such as in the skin and in the intestine. 
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Figure 6. ZA upregulates TRAIL on NK cells. In a co-culture of NK cells and autologous 
monocytes, addition of ZA in combination with IL-2 induces secretion of IFNγ from the 
monocytes which in turn triggers upregulation of TRAIL on NK cells. ZA-primed NK cells display 
enhanced cytotoxicity against TRAIL-sensitive tumor targets in vitro and in vivo.  
3.2    Augmenting NK cell migration toward solid tumors 
NK cell therapy has been most effective against hematological malignancies but has yet to 
generate strong anti-tumor effects in patients with solid tumors. Although studies have shown 
that NK cells are better at lysing tumor target cells of hematopoietic origin compared to tumor 
cells derived from other tissues [323], several investigators have shown that expression of 
both ULBPs and NCRs is low on leukemic blasts while loss of HLA class I expression is less 
frequent in AML than in melanoma and other solid tumors [324, 325]. Insufficient homing of 
NK cells has been proposed as one of the main contributing factors to the discrepancy in 
clinical effect between hematological and solid tumors [233, 236, 326]. In line with this 
hypothesis, it has been shown in several cancer types that intratumoral infiltration of NK cells 
correlates with good prognosis [115-117, 327, 328]. It has been demonstrated that in 
melanoma patients receiving indium-labeled lymphocytes without pre-conditioning, only a 
fraction of a percent of the infused lymphocytes actually end up at the tumor site [240]. There 
have been several attempts made at augmenting the homing capacity of lymphocytes by 
inducing chemokine receptor expression, either by stimulation or by viral transduction [273, 
329]. Other studies have showed that induced secretion of chemokines from tumor cells or 
tumor-associated cells results in increased directed lymphocyte homing and infiltration [118].  
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3.2.1    Paper III 
In this paper we aimed to demonstrate the clinical significance of CXCL10-induced migration 
by adoptively transferred ex vivo expanded NK cells. There are several conflicting studies on 
how the expression of CXCR3 is modulated on NK cells upon activation [330, 331]. By using 
an NK cell expansion protocol involving high dose IL-2 and a feeder cell population of 
irradiated EBV-transformed B cells, we achieved a more than 10-fold increase in surface 
expression of CXCR3. In transwell migration assays we showed that expanded NK cells 
migrated better towards both recombinant CXCL10 and IFNγ-stimulated tumor cells (figure 
7). To confirm that an augmented CXCL10-directed homing of NK cells would have an effect 
on tumor growth, we established a xenogeneic mouse model. In the first step we inoculated 
mice with tumors that were negative for CXCL10-production subcutaneously in the left flank 
and with tumors that were lentivirally transduced to overexpress CXCL10 in the right flank. 
When tumors became palpable the mice were treated with fluorescently labeled expanded 
human NK cells and migration of the NK cells was monitored using in vivo imaging. This 
model demonstrated that NK cells preferentially migrated towards the CXCL10-positive 
tumors. In a second xenograft model, we implanted CXCL10-negative tumors in one group of 
mice and CXCL10-positive tumors in another group. Both groups were injected with 
fluorescently labeled NK cells. By measuring the fluorescence intensity of excised tumors we 
found that NK cell infiltration was higher in the CXCL10-positive tumors than in CXCL10-
negative tumors. The impact of CXCR3-ligand expression in tumors on the migration and 
infiltration of lymphocytes has been exemplified both in patients and in mouse models [29, 
118]. However, we show for the first time that CXCL10-induced migration of adoptively 
transferred human NK cells has a significant impact on the anti-tumor effect of the infused 
NK cells. 
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Figure 7. IFNγ-induced secretion of CXCL10 chemoattracts CXCR3-positive NK cells. Tumors 
can be stimulated to secrete the NK cell-attracting chemokine CXCL10 by stimulation with 
the pro-inflammatory cytokine IFNγ. Although the IFNγ-stimulation leads to upregulation of 
MHC class I on tumor cells thus conveying an increased resistance to NK cell lysis, the 
augmented secretion of CXCL10 leads to increased capacity of tumor cells to chemoattract 
NK cells expressing the chemokine receptor CXCR3.  
3.3    Finding novel tumor targets for NK cell therapy 
NK cell therapy against solid tumors has been tested only in a few trials and in a very limited 
range of malignancies. Although clinical responses of NK cell treatment has been observed in 
RCC, malignant glioma and metastatic breast cancer, durable tumor regression has so far been 
limited [332-334]. For T cell therapy, melanoma has been identified as the single most 
immunogenic tumor type, although for NK cell treatment that has not been the case [335]. 
The identification of tumor types that display the characteristics needed, at least in theory, to 
be targetable by activated NK cells is one important aspect to consider on the path to 
successful treatment of cancer patients with NK cell therapy. 
3.3.1    Paper IV 
The aim of this paper was to study the interactions between NK cells and ATC cells in terms 
of sensitivity to lysis by expanded NK cells as well as proneness to chemoattract NK cells 
(figure 8). The idea of the project was formulated when we were screening cell lines for their 
response to doxorubicin in terms of sensitivity to NK cell lysis. In all of the ATC cell lines 
that we tested we observed sensitivity to lysis by NK cells at a level that we had not seen with 
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any other cell lines irrespective of histiotype. We continued by obtaining a larger panel of 
ATC cell lines, of which half were in low-passage, and proceeded with elucidating the 
mechanisms behind the unprecedented sensitivity. We established that the NKG2D-pathway 
was involved in NK cell-mediated killing of ATC cell lines and further analysis revealed that 
ULBP2 was highly expressed on ATC cells and that the level of expression correlated with 
sensitivity to NK cell-mediated lysis. Blocking of NKG2D on NK cells or ULBP2 on tumor 
cells in a co-culture abrogated the NK cell-mediated lysis of ATC cells.  
Analysis of fine-needle aspirates (FNA) and PBMCs from untreated ATC patients revealed a 
suppressed phenotype of tumor-infiltrating NK cells compared to NK cells from peripheral 
blood. The total frequency of NK cells among lymphocytes and the level of CD56dim NK cells 
in the NK cell population were lower in FNA than in PBMCs. Several investigators have 
reported a skewed CD56dim/CD56bright ratio in chronic inflammatory conditions such as 
tuberculosis and rheumatoid arthritis [336, 337]. In cancer, which in many cases also can be 
considered as a site of chronic inflammation, it has been reported that circulating CD56dim NK 
cells are prone to undergo apoptosis [338]. It has also been proposed that CD56dim NK cells 
are more susceptible to ROS produced in the tumor microenvironment due to them having 
lower anti-oxidative capacity compared to CD56bright NK cells [150]. Although our analysis of 
CXCR3-expression in ATC patients only involves three samples we found that in two out of 
three patients, the CD56dim NK cells had a lower expression of CXCR3 compared to 
CD56bright NK cells. This could provide an alternative explanation to the skewed 
CD56dim/CD56bright in ATC tumors due to preferential migration of CD56bright NK cells to the 
tumor site. In ATC patient samples we also observed that NKG2D surface expression was 
lower in FNA compared with PBMCs although CD69 expression was elevated in FNA. 
Expression of CD69 on NK cells is a sign of activation but can also be a general inhibitor of 
immune responses against tumors. NK cell cytotoxicity was augmented in CD69-/- mice as a 
consequence of altered cytokine signaling, including reduced lymphocyte secretion of TGFβ 
and increased release of MCP-1 and IL-1β [339].  
We wanted to investigate if the poor condition of the NK cells was a result of immune 
suppressive factors secreted from the tumor, so therefore we cultured NK cells in the presence 
of supernatant from ATC cell lines. We found that tumor-derived supernatants from COX-2-
positive cell lines where more suppressive of NKG2D-expression on NK cells than 
supernatant from COX-2-negative cell lines. Furthermore, when we neutralized PGE2 in the 
co-culture, both NKG2D-expression and cytotoxic activity of NK cells was restored to 
normal. The importance of NKG2D-mediated surveillance and elimination of tumors has been 
demonstrated in an NKG2D-deficient mouse model [340]. In in vitro culture, we observed 
that ATC cell lines were prone to secrete high levels of CXCL10 after stimulation with 
minute doses of IFNγ. Consequently, CXCR3-positive NK cells were able to actively migrate 
toward supernatant from IFNγ-treated ATC tumors in a transwell migration assay. In line with 
this finding, we found a dramatically increased percentage of CXCR3-positive NK cells in 
FNA compared to peripheral blood NK cells. Taken together, our findings indicate that ATC 
is a potential target for adoptive NK cells therapy due to sensitivity to NKG2D-mediated lysis 
by NK cells and proneness to secrete CXCL10.  
 
49 
 
 
 
 
 
 
 
 
 
Figure 8. ATC cells are sensitive to NK cell lysis and chemoattract CXCR3-positive NK cells. 
The highly aggressive tumor type ATC express high levels of the NK cell activating ligand 
ULBP2 rendering them sensitive to NKG2D-mediated lysis by NK cells without prior sensitization. 
Moreover, ATC cells are prone to secrete high levels of the NK cell-attracting chemokine 
CXCL10. Taken together, these characteristics of ATC cells make ATC a promising target for 
NK cell-based therapies. 
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Concluding remarks 
Successful NK cell-based immunotherapy relies on a variety of factors that are needed to 
ensure that NK cells reach their target and are able to eliminate it without being suppressed in 
the process. Therefore, continued studies on the intrinsic mechanisms of NK cell biology and 
regulation are essential in order to develop safe and efficient therapies. In a pre-clinical 
setting, screening of pharmaceutical capable of augmenting NK cell cytotoxicity and 
improving the chemotactic capacity of NK cells are important in order to find more effective 
ways of priming NK cells before infusion. In addition, by testing how chemotherapy agents 
and small molecules can be used to sensitize tumors to NK cell lysis and act in synergy with 
NK cells, will allow for the development of new combination strategies.  
NK cell therapy is a bona fide individualized treatment form where the patient and the 
particularities of that patient’s tumor need to be in focus. This requires a careful analysis of 
the parameters that will influence the chances of success, including donor selection and 
priming of the cellular product, choice of preconditioning and evaluation of predictive 
markers for each individual patient.  
With ongoing clinical testing of immunomodulatory therapeutics and different combination 
strategies, which are nowadays carefully immune monitored, our knowledge of how NK cells 
interact with tumors and other components of the immune system will continue to increase. 
This knowledge, in combination with technical advances in the typing and selection of 
suitable NK cell donors and processing of cellular products, our ability to design effective NK 
cell therapies will likely increase in the future.  
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